Anzeige
Mehr »
Login
Mittwoch, 29.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Künstliche Intelligenz lässt die Nachfrage explodieren - so profitieren Anleger
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JKVH | ISIN: IE00B56GVS15 | Ticker-Symbol: 8AK
Frankfurt
29.05.24
08:34 Uhr
21,600 Euro
0,000
0,00 %
1-Jahres-Chart
ALKERMES PLC Chart 1 Jahr
5-Tage-Chart
ALKERMES PLC 5-Tage-Chart
RealtimeGeldBriefZeit
21,60022,00016:10
21,60021,80016:11

Aktuelle News zur ALKERMES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAlkermes plc: Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024244- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -...
► Artikel lesen
Do6 Analysts Assess Alkermes: What You Need To Know2
14.05.Alkermes plc: Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences298? Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for People Living with Schizophrenia or Bipolar I Disorder...
► Artikel lesen
02.05.7 Analysts Assess Alkermes: What You Need To Know1
02.05.Alkermes Completes $91M Sale of Athlone Facility to Novo Nordisk8
02.05.Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates1
02.05.Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk271DUBLIN, May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk....
► Artikel lesen
01.05.Alkermes plc. - 10-Q, Quarterly Report1
01.05.Alkermes plc Q1 Earnings Summary207WASHINGTON (dpa-AFX) - Below are the earnings highlights for Alkermes plc (ALKS):Earnings: $36.83 million in Q1 vs. -$41.85 million in the same period last year. EPS: $0.21 in Q1 vs. -$0.25...
► Artikel lesen
01.05.Alkermes plc Reports First Quarter 2024 Financial Results206- First Quarter Revenues of $350.4 Million - - GAAP Net Income from Continuing Operations of $38.9 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.23...
► Artikel lesen
01.05.Alkermes plc. - 8-K, Current Report2
30.04.Alkermes Q1 2024 Earnings Preview2
24.04.Alkermes plc: Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1428DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS...
► Artikel lesen
22.04.Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?1
17.04.Alkermes plc: Alkermes to Report First Quarter Financial Results on May 1, 2024267DUBLIN, April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss...
► Artikel lesen
11.04.Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study1
09.04.Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says1
09.04.Breaking Down Alkermes: 5 Analysts Share Their Views1
09.04.US STOCKS Bloom Energy, Hecla Mining, Alkermes19
09.04.Alkermes' sleep disorder drug shows promise in early-stage study1
Seite:  Weiter >>
132 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1